Breadcrumb

null Peter Siegel, PhD

Investigator, RI-MUHC

Cancer Research Program

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Endocrinology, MUHC

 

Keywords

cancer cell migration/invasion • metastasis • tumor microenvironment • tumor/stromal interactions • experimental therapeutics

Research Focus

My research focuses on elucidating the cellular and molecular mechanisms that promote cancer metastasis, which represents the deadliest aspect of the disease. Our research program can be divided into three broad themes: the first is the identification of key tumour cell intrinsic molecules, signalling pathways and metabolic strategies that enable cancer cells to migrate, invade and metastasize. The second theme investigates the interactions between cancer cells and the primary and metastatic microenvironments in which they grow. The immediate tumour microenvironment includes the extracellular matrix components, resident parenchymal cells that comprise different organs/tissues and the infiltrating innate and adaptive immune cells, all of which influence the growth and spread of cancer cells. The third theme focuses on how these key molecules, pathways or tumour/stromal interactions can be targeted therapeutically.

Selected Publications

Click on Pubmed to see my current publications list

  • M. Dankner, S.M. Maritan, N. Priego, G. Kruck, A. Nkili-Meyong, J. Nadaf, R. Zhuang, M.G. Annis, D. Zuo, A. Nowakowski, M. Biondini, A. Kiepas, C. Mourcos, P. Le, F. Charron, Y. Inglebert, P. Savage, L. Théret, M-C. Guiot, R.A. McKinney, W.J. Muller, M Park, M. Valiente, K. Petrecca, and P.M. Siegel. (2024). Invasive growth of brain metastases is linked to CHI3L1 released from pSTAT3-positive astrocytes. Neuro-Oncology (Online ahead of Print).

  • E. Karimi, M.W. Yu, S.M. Maritan, L. Perus, M. Dankner, M. Rezanejad, P. Fallah, M. Sorin, D. Zuo, D.J. Kloosterman, Y. Wei1, S. Lam, I. Watson, M. Park, L. Akkari, K. Petrecca, M-C Guiot, P.M. Siegel*, L.A. Walsh* and D.F. Quail*. (2023). Highly multiplexed imaging of the brain tumor microenvironment reveals immunological spatial networks that predict survival. Nature. 614(7948): 555-563. *Co-corresponding Authors.

  • M. Biondini, A. Kiepas, L. El-Houjeiri, M.G. Annis, B.E. Hsu, A-M Fortier, G. Morin, J.A. Martina, I. Sirois, A. Aguilar-Mahecha, T. Gruosso, S. McGuirk, A.A.N. Rose, U.M. Tokat, R.M. Johnson, O. Sahin, E. Bareke, J. St-Pierre, M. Park, M. Basik, J. Majewski, R. Puertollano, A. Pause,, S. Huang, T. Keler and P.M. Siegel. (2022). HSP90 inhibitors induce GPNMB cell surface expression and sensitize breast cancer cells to Glembatumumab Vedotin. Oncogene. 41(12): 1701-1717.

  • L. El-Houjeiri, M. Biondini, M. Paquette, H. Kuasne, A. Pacis, M. Park, P.M. Siegel* and A. Pause*. (2021). Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. J Clin. Invest. 131(22). E144871. *Co-corresponding Authors.

  • S. Tabariès, M.G. Annis, A. Lazaris, S. Petrillo, A. Abdellatif, V. Palmieri, J. Chabot, R. Johnson, S. van Laere, C. Verhoef, Y. Hachem, S. Yumeen, N. Meti, A. Omeroglu, G. Altinel, Z-H. Gao, D. Grünhagen, P. Vermeulen, P. Metrakos*, P.M. Siegel*. (2021). Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Comm Biol. 4(1) 657. *Co-corresponding Authors.